EDIT vs FDMT โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
EDIT Captures Institutional Edge (2โ1 Pillars ยท 2โ6 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Editas Medicine, Inc. Common Stock (EDIT) driven by superior Growth & Margin, Options & Structure while FDMT counters with relative strength in Momentum & Technical. Fundamentally, EDIT trades at N/M Forward P/E with -167.0% operating margin (+37.4% YoY revenue) versus FDMT at N/M Forward P/E and -222.7% operating margin (+4505.6% YoY). In options structure, EDIT sits in BREAKDOWN (38th %ile IV; Dealer Gamma Walls on Pro) against FDMT sits in BREAKDOWN (10th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | EDIT Revenue | FDMT Revenue | EDIT Op. Margin | FDMT Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $30M | N/A | -356.1% | N/A | EDIT |
| FY2019 | $20M | $10M | -686.4% | -729.4% | EDIT |
| FY2020 | $90M | $10M | -148.6% | -424.0% | EDIT |
| FY2021 | $30M | $20M | -756.1% | -395.5% | FDMT |
| FY2022 | $20M | $0M | -1146.3% | -3516.5% | EDIT |
| FY2023 | $80M | $20M | -216.6% | -544.6% | EDIT |
| FY2024 | $30M | $0M | -777.2% | -507678.4% | EDIT |
| FY2025 | $40M | $90M | -394.9% | -187.2% | FDMT |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | EDIT | FDMT | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $336.5M | $669.3M | Larger Scale | FDMT |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +37.4% | +4505.6% | Higher Growth | FDMT |
| Operating Margin (TTM) Profitability | -167.0% | -222.7% | Higher Margin | EDIT |
| Net Profit Margin Profitability | -144.9% | -208.6% | Higher Margin | EDIT |
| Return on Equity (ROE) Capital Efficiency | -147.4% | -56.7% | Higher ROE | FDMT |
| 52-Week Range Position Momentum | 11% ($2โ$4) | 47% ($7โ$17) | Stronger Trend | FDMT |
| Beta / 30D Volatility Risk Regime | 2.32ฮฒ ยท 102% Vol | 1.89ฮฒ ยท 90% Vol | Lower Realized Risk | FDMT |
| Unified Institutional Score Composite Signal | 48.4 / 100 (HOLD) | 51.3 / 100 (HOLD) | Higher Composite | FDMT |